141 related articles for article (PubMed ID: 9627018)
1. Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction.
Jouvenne P; Vannier E; Dinarello CA; Miossec P
Arthritis Rheum; 1998 Jun; 41(6):1083-9. PubMed ID: 9627018
[TBL] [Abstract][Full Text] [Related]
2. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids.
Arend WP; Malyak M; Smith MF; Whisenand TD; Slack JL; Sims JE; Giri JG; Dower SK
J Immunol; 1994 Nov; 153(10):4766-74. PubMed ID: 7963543
[TBL] [Abstract][Full Text] [Related]
3. IL-1 beta, IL-1 receptor antagonist and soluble type II IL-1 receptor in synovial fluid of patients with temporomandibular disorders.
Tominaga K; Habu M; Sukedai M; Hirota Y; Takahashi T; Fukuda J
Arch Oral Biol; 2004 Jun; 49(6):493-9. PubMed ID: 15099807
[TBL] [Abstract][Full Text] [Related]
4. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist.
Smeets RL; Joosten LA; Arntz OJ; Bennink MB; Takahashi N; Carlsen H; Martin MU; van den Berg WB; van de Loo FA
Arthritis Rheum; 2005 Jul; 52(7):2202-11. PubMed ID: 15986350
[TBL] [Abstract][Full Text] [Related]
5. Profile of soluble cytokine receptors in Crohn's disease.
Gustot T; Lemmers A; Louis E; Nicaise C; Quertinmont E; Belaiche J; Roland S; Van Gossum A; Devière J; Franchimont D
Gut; 2005 Apr; 54(4):488-95. PubMed ID: 15753533
[TBL] [Abstract][Full Text] [Related]
6. Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy.
Vannier E; Kaser A; Atkins MB; Fantuzzi G; Dinarello CA; Mier JW; Tilg H
Eur Cytokine Netw; 1999 Mar; 10(1):37-42. PubMed ID: 10210771
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma.
Ricote M; García-Tuñón I; Bethencourt FR; Fraile B; Paniagua R; Royuela M
Cancer; 2004 Apr; 100(7):1388-96. PubMed ID: 15042672
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.
Bendele A; McAbee T; Sennello G; Frazier J; Chlipala E; McCabe D
Arthritis Rheum; 1999 Mar; 42(3):498-506. PubMed ID: 10088773
[TBL] [Abstract][Full Text] [Related]
9. Differential binding of human interleukin-1 (IL-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type I receptors.
Svenson M; Nedergaard S; Heegaard PM; Whisenand TD; Arend WP; Bendtzen K
Eur J Immunol; 1995 Oct; 25(10):2842-50. PubMed ID: 7589081
[TBL] [Abstract][Full Text] [Related]
10. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model.
Chabaud M; Miossec P
Arthritis Rheum; 2001 Jun; 44(6):1293-303. PubMed ID: 11407688
[TBL] [Abstract][Full Text] [Related]
11. Production of interleukin (IL)-1beta, IL-1 receptor antagonist and IL-10 by blood mononuclear cells in chronic arthritis.
Andersen LS; Petersen J; Bendtzen K
Cytokine; 2000 Jan; 12(1):62-8. PubMed ID: 10623444
[TBL] [Abstract][Full Text] [Related]
12. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease.
Ludwiczek O; Vannier E; Borggraefe I; Kaser A; Siegmund B; Dinarello CA; Tilg H
Clin Exp Immunol; 2004 Nov; 138(2):323-9. PubMed ID: 15498044
[TBL] [Abstract][Full Text] [Related]
13. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
[TBL] [Abstract][Full Text] [Related]
14. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients.
Sirota P; Meiman M; Herschko R; Bessler H
Psychiatry Res; 2005 Apr; 134(2):151-9. PubMed ID: 15840416
[TBL] [Abstract][Full Text] [Related]
15. [Role of interleukin-18, interleukin-1beta and its soluble receptor (sIL-1RII) in early and late Lyme borreliosis].
Pietruczuk A; Swierzbińska R; Pietruczuk M; Hermanowska-Szpakowicz T
Pol Merkur Lekarski; 2004 Nov; 17(101):446-50. PubMed ID: 15754629
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-1beta, interleukin-1 receptor antagonist, and interleukin-1 soluble receptor II in temporomandibular joint synovial fluid from patients with chronic polyarthritides.
Alstergren P; Benavente C; Kopp S
J Oral Maxillofac Surg; 2003 Oct; 61(10):1171-8. PubMed ID: 14586853
[TBL] [Abstract][Full Text] [Related]
17. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis.
Muzaffer MA; Dayer JM; Feldman BM; Pruzanski W; Roux-Lombard P; Schneider R; Laxer RM; Silverman ED
J Rheumatol; 2002 May; 29(5):1071-8. PubMed ID: 12022325
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.
Jiang Y; Genant HK; Watt I; Cobby M; Bresnihan B; Aitchison R; McCabe D
Arthritis Rheum; 2000 May; 43(5):1001-9. PubMed ID: 10817552
[TBL] [Abstract][Full Text] [Related]
19. Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease.
Lindberg C; Chromek M; Ahrengart L; Brauner A; Schultzberg M; Garlind A
Neurochem Int; 2005 Jun; 46(7):551-7. PubMed ID: 15843049
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory activity of IL-1 receptor antagonist depends on the balance between binding capacity for IL-1 receptor type 1 and IL-1 receptor type II.
Ruggiero P; Bossù P; Macchia G; Del Grosso E; Sabbatini V; Bertini R; Colagrande A; Bizzarri C; Maurizi G; Di Cioccio V; D'Andrea G; Di Giulio A; Frigerio F; Grifantini R; Grandi G; Tagliabue A; Boraschi D
J Immunol; 1997 Apr; 158(8):3881-7. PubMed ID: 9103457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
